Screening High-Concentration Protein-Protein Interactions

Monoclonal antibodies (mAbs) treatment requires relatively large doses, often in the range of several mg/kg bodyweight. The volume restrictions (less than 1.5ml) for SC injections, therefore, necessitate the development of high concentration formulations.